Format

Send to

Choose Destination
See comment in PubMed Commons below
Otolaryngol Head Neck Surg. 2013 Jun;148(6):1003-6. doi: 10.1177/0194599813484685. Epub 2013 Mar 27.

Considerations for initial dosing of botulinum toxin in treatment of adductor spasmodic dysphonia.

Author information

  • 1Department of Otolaryngology, University of Miami Miller School of Medicine, Miami, Florida 33136, USA. DRosow@med.miami.edu

Abstract

OBJECTIVES:

To assess the effect on voice improvement and duration of breathiness based on initial dose of onabotulinum toxin A (BTX-A) in the management of adductor spasmodic dysphonia (SD) and to compare voice outcomes for initial bilaterally injected doses of 1.25 units (group A) vs 2.5 units (group B) of BTX-A.

STUDY DESIGN:

Case series with chart review of patients with adductor SD treated at a tertiary care facility from 1990 to 2011.

SETTING:

Academic subspecialty laryngology practice.

METHODS:

Demographic data (age and sex), voice rating, duration of voice improvement, and breathiness were evaluated and compared between groups A and B using the Student t test and χ(2) analysis.

RESULTS:

Of 478 patients identified, 305 (223 in group A, 82 in group B) patients met inclusion criteria. The average age was 56.2 years in group A and 57.4 years in group B (P = .5). The female to male ratio was 2.91 for group A vs 3.56 for group B (P = .61). Good voice outcomes (grade 3 or 4) were reported by 91% of group A patients vs 94% of group B (P = .75). The average duration of voice improvement was 99.7 days for group A and 108.3 days for group B (P = .54). The average duration of breathiness was 10.88 days for group A vs 15.42 days for group B (P = .02).

CONCLUSION:

Patients injected with 1.25 units bilaterally had a statistically significant shorter duration of breathiness without a statistically significant difference in clinical effectiveness or voice outcome. It is therefore recommended that a relatively low initial BTX-A dose be used with subsequent titration to achieve improved voice outcomes.

KEYWORDS:

Botox; botulinum toxin; dosing; dystonia; neurolaryngology; spasmodic dysphonia; voice

PMID:
23535709
DOI:
10.1177/0194599813484685
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center